Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

STUDY AND PROTOCOL NUMBER

EXPAND CBAF312A2304

STUDY DETAILS

A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis

Further information

ClinicalTrials.gov Identifier: NCT01665144

https://clinicaltrials.gov/ct2/show/NCT01665144?term=BAF312&rank=4